Zawtar al-Gharbiyah (AFP) | 22/07/2026 - 09:10:47 | Lebanon PM says Beirut working for 'complete Israeli withdrawal'
Paris (AFP) | 22/07/2026 - 09:03:25 | France's environment minister says will resign Wednesday over pesticide bill
London (AFP) | 22/07/2026 - 08:14:28 | UK inflation falls more than expected to 2.6% in June
Pontevès (AFP) | 22/07/2026 - 07:26:22 | Wildfire in southern France contained: firefighters
Manila (AFP) | 22/07/2026 - 04:28:28 | Allowing Iran control of Hormuz 'dangerous precedent', Rubio tells ASEAN
Tehran (AFP) | 22/07/2026 - 03:16:41 | Air defence activated in Tehran: state media
Washington (AFP) | 22/07/2026 - 01:53:35 | US military says begins 11th straight night of strikes on Iran
Washington (AFP) | 22/07/2026 - 01:11:23 | Trump says imported generic drugs to face 100% tariff from August 2028
Georgetown (AFP) | 22/07/2026 - 01:10:58 | Guyana govt raises capsized ferry death toll to 53
Gusau (AFP) | 22/07/2026 - 00:26:42 | Nigerian gang abducts at least 40 people: local sources
A cookie is a small piece of data (text file) that a website – when visited by a user – asks your browser to store on your device in order to remember information about you, such as your language preference or login information.
Samsung Bioepis Co., Ltd. today announced the launch of OPUVIZ™ 40 mg/mL solution for injection in a vial, a biosimilar referencing Eylea1 (aflibercept), across Europe, starting today. OPUVIZ marks the fifth biosimilar product to be directly commercialized by Samsung Bioepis. It builds on other key biosimilar milestones in Europe this year, including the initiation of direct commercialization of BYOOVIZ™ (ranibizumab) 10 mg/mL solution for injection in a vial, as well as the launch of XBRYK™ ...
